

Supporting Information

Conjugated Platinum(IV)-Peptide Complexes for Targeting Angiogenic Tumor Vasculature

Sumitra Mukhopadhyay,^{†,¶} Carmen M. Barnés,^{‡,¶,*} Ariel Haskel,[†] Sarah M. Short,[‡] Katie R. Barnes,[†] and Stephen J. Lippard^{†,*}

Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, and Vascular Biology Program, Children's Hospital and Harvard Medical School, Boston, Massachusetts 02115

[¶]These authors contributed equally to the work

*To whom correspondence should be addressed.

Email: carmen.barnes@childrens.harvard.edu, lippard@mit.edu

[†] Massachusetts Institute of Technology

[‡] Harvard Medical School

Running title: Pt(IV)-Peptide Complexes for Angiogenic Targeting




Figure S1. Reverse-phase HPLC purification of Pt(IV)-RGD conjugates, **2a** and **2b** (C18 semi-preparatory column, 40 mm x 250 mm, linear gradient from 100% H₂O to 15% acetonitrile over 30 min).




Figure S2a. ESI-MS of monoconjugated Pt-RGD complex, **2a** (the $[M+H]^+$ peak).




Figure S2b. ESI-MS of the diconjugated Pt-RGD complex, **2b** (the $[M+H]^+$ peak).




Figure S2c. ESI-MS of diconjugated Pt-RGD complex, **2b** (the $[M + 2H]^{2+}/2$ peak).





Figure S3. Fluorescence-activated cell sorting of primary endothelial cells and tumor cell lines labeled with monoclonal antibodies to integrin $\alpha_v\beta_3$, integrin $\alpha_v\beta_5$, and aminopeptidase N (CD13).

A. Monoconjugated Platinum-Peptide Compounds



B. Diconjugated Platinum-Peptide Compounds




Figure S4. Concentration-response assay of platinum compounds on U87 cells. Selected monofunctionalized platinum(IV) complexes along with cisplatin, and **1(A)**. Selected difunctionalized platinum(IV) complexes along with cisplatin, and **1(B)**. Cells were treated for 72 h with each complex and counted with the use of a Coulter counter.